Livforsakringsbolaget Skandia Omsesidigt Raises Stock Holdings in AbbVie Inc. $ABBV

Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 7.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 167,270 shares of the company’s stock after acquiring an additional 11,800 shares during the quarter. AbbVie makes up approximately 1.4% of Livforsakringsbolaget Skandia Omsesidigt’s holdings, making the stock its 18th biggest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in AbbVie were worth $42,018,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie during the fourth quarter valued at about $28,000. Imprint Wealth LLC increased its holdings in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the period. Burk Holdings LLC purchased a new position in AbbVie during the 2nd quarter valued at about $30,000. Legacy Wealth Managment LLC ID raised its position in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in AbbVie during the 4th quarter valued at approximately $31,000. Institutional investors own 70.23% of the company’s stock.

Get AbbVie alerts:

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $256.27 on Monday. The firm has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29. The stock has a 50 day moving average price of $254.66 and a 200-day moving average price of $230.05. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio is currently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent analyst reports. Citigroup lifted their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. BMO Capital Markets raised their price target on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Morgan Stanley reiterated an “overweight” rating and issued a $296.00 price target on shares of AbbVie in a report on Monday, August 3rd. HSBC reissued a “buy” rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $275.95.

Get Our Latest Stock Report on ABBV

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Featured Stories

• Five stocks we like better than AbbVie
• AI Token Costs Are Changing the Hardware vs. Software Debate
• 3 ETFs That Could Move as Rate Expectations Shift
• 3 Stocks With September Catalysts Investors Shouldn’t Ignore
• Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.